AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01335373 — intervention group
Intervention type: DRUG
Intervention: Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)
Description: Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.
Study NCT02771457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab at weeks 0 and 8
Description: For physicians who do not feel comfortable enrolling patients in a randomized trial of infliximab re-induction they will have the option of enrolling their patients in an arm that resumes maintenance therapy only instead at 0 and 8 weeks.
Study NCT02668744 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intervention
Description: The intervention consists of building edible gardens at each the eight participating and eligible schools. Educators will be provided to lead 18 gardening, nutrition and cooking lessons throughout the school year intervention to all 3-5th grade students. Nine gardening, nutrition, and cooking classes will be taught to parents every month. Garden Leadership Coalitions (GLCs), made up of parents, teachers and school staff, will be formed and training/resources provided to help with adoption of the program. Training and resources will be provided to the GLCs and teachers in the 2nd year to assist with sustainability.
Study NCT02668744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention consists of building edible gardens at each the eight participating and eligible schools. Educators will be provided to lead 18 gardening, nutrition and cooking lessons throughout the school year intervention to all 3-5th grade students. Nine gardening, nutrition, and cooking classes will be taught to parents every month. Garden Leadership Coalitions (GLCs), made up of parents, teachers and school staff, will be formed and training/resources provided to help with adoption of the program. Training and resources will be provided to the GLCs and teachers in the 2nd year to assist with sustainability.
Study NCT04539925 — intervention group
Intervention type: OTHER
Intervention: Acute coronary syndrome
Description: The effect of air pollution on acute coronary syndrome
Study NCT01814826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN4924
Description: MLN4924 intravenously (IV) in AML participants in a 28-day cycle:~* MLN4924 on Days 1, 3, and 5 for Cycle 1 and all subsequent cycles
Study NCT01814826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine (IV) or subcutaneously in AML participants in a 28-day cycle:~- Azacitidine Days 1, 2, 3, 4, 5, 8, 9 in Cycle 1 and for all subsequent cycles
Study NCT02379312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Very low energy aerated beverage
Study NCT02379312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal energy aerated beverage 1
Study NCT02379312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal energy aerated beverage 2
Study NCT02379312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal energy aerated beverage 3
Study NCT03184116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual intervention
Description: Individual intervention based on a cognitive-behavioral program Reasoning \& Rehabilitation
Study NCT02712281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autism MEAL Plan
Description: The Autism MEAL plan includes education on feeding issues and behavior management, and specific strategies to expand dietary diversity. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician. The first three sessions focus on understanding feeding problems and behavior management strategies in children with ASD.The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson.~The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson.
Study NCT02712281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education
Description: The Parent Education study arm includes 10 sessions focusing on the following topics: understanding Autism Spectrum Disorder (ASD), clinical assessments for ASD, development in children with ASD, medical and genetic comorbidities in ASD, family and sibling issues, treatment alternatives, and education and treatment planning. The Parent Education arm does not include topics related to feeding problems or feeding specific interventions. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician.~Children randomized to Parent Education will be offered the Autism MEAL Plan after completing the 10-week randomized trial.
Study NCT02227056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
Study NCT04252248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacogen
Description: Intravenous (i.v.) infusion of 20 mg/m2 over 1 hour repeated daily for 5 days starting on day 1. Single repetition of cycle on day 29.
Study NCT03729661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nasal High Flow Therapy
Description: Use of Nasal High Flow Therapy during CT and treatment
Study NCT03091595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg E4/3 mg DRSP
Description: 15 mg E4/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
Study NCT03692247 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Smartphone-based Music Intervention
Description: The smartphone-based music intervention (Unwind) is a music protocol that gathers basic information from the patient including a 0-10 pain scale and 0-10 anxiety scale as well as recorded heart rate. Using these variables, a machine learning protocol pieces together a music intervention between 5-20 minutes long. The duration of the intervention can be controlled by the patient or experimenter. No identifying data is kept on the smartphone.
Study NCT01127932 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation for substance abuse
Description: This active control provides detailed information about substance use, suicide risk, and depression to those enrolled.
Study NCT00780234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIOGLITAZONE VS. PLACEBO 30 mg
Description: Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-~activated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials. fluid retention may result in new onset heart failure or exacerbation of existing heart failure. Small risk of hypoglycemia, anemia, myalgia, bone fracture, headache, and macular retinal edema exists. There is insufficient information to confirm its safety in Pregnancy/Breastfeeding. Bladder cancer is more serious but rare.
Study NCT03091595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mcg EE/3 mg DRSP
Description: 20 mcg EE/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
Study NCT01127932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for suicide in Substance abuse
Description: The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
Study NCT02938247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High caloric, high protein ONS
Study NCT02419378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Study NCT02229786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buscopan® plus
Study NCT02229786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buscopan®
Study NCT02229786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Study NCT02229786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03302403 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR-CD19 T cell
Description: Self-controlled dose escalation and classic 3+3 dose escalation will be applied.
Study NCT03302403 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR-BCMA T cell
Description: Self-controlled dose escalation and classic 3+3 dose escalation will be applied.
Study NCT03302403 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR-GPC3 T cell
Description: Self-controlled dose escalation and classic 3+3 dose escalation will be applied.
Study NCT03302403 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR-CLD18 T cell
Description: Self-controlled dose escalation and classic 3+3 dose escalation will be applied.
Study NCT03302403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion.
Study NCT03302403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion.
Study NCT01553292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECALMIST
Description: Labelled catheter at level of the lips (6 cm plus weight) will inserted through the vocal cords under direct vision using a standard laryngoscope without premedication while maintaining CPAP. 5 ml/kg surfactant syringe will be connected to the catheter hub and 0.25-0.5 ml was administered; then the syringe will be disconnected from the catheter to observe the surfactant moving up and down or coming back as indication of accurate intubation of the trachea. The surfactant the slowly administer by boluses of 0.25-0.5 ml over 20-30 seconds with 10 seconds apart. At the end of the procedure, the operator flushed the catheter with 0.5 ml of air before removing the catheter while maintaining CPAP
Study NCT01553292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECALMIST
Description: Vascular catheter of 1.6 French size of 133 mm length 16 gauge used to deliver the BLES; a large volume surfactant while maintain CPAP
Study NCT03369015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Description: 10 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
Study NCT01052259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxyspergualin
Description: 100mg/vial as active substance; Deoxyspergualin at 3-5 mg/kg/day by 1-3 iv infusion will be given once a day for 5 to 7 days each cycle every month; Total cycle treatment will be 6.
Study NCT03369015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg d-amphetamine
Description: 20 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
Study NCT04997213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback exercises
Description: Biofeedback system is a center of pressure-controlled video game-based exercise system designed for patients with neurological and orthopedic diseases and provides balance training using auditory, visual, and pressure biofeedback. The system contains several games, each designed to focus on a different component of balance. Biofeedback is provided by means of a monitor in front of the patient. The balance exercises program was involved a total of 18 sessions, each lasting 20 min, three times a week for six weeks, and was individually tailored based on the patient's tolerance and current motor and sensorial capacities. All patients performed conventional exercises.
Study NCT04997213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercises
Description: Classic balance exercises were performed (two-leg stance, semi-tandem stance, tandem stance, standing on one leg, tandem walking, turning completely around, heel-to-toe stance, and standing with the eyes closed). Patients with balance disorder first could be commenced balance training in a seated position before progressing to standing exercises, to the extent that these could be tolerable.
Study NCT04661852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: PO (dose and schedule based upon dose level and nomogram)
Study NCT05198999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic-based Plyometric Exercises
Description: The Aqua-PLYO group received the aquatic plyometric exercise training for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association
Study NCT05198999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
Study NCT04661852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: IV, over 30 minutes (schedule based upon dose level)
Study NCT02179242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehab
Study NCT03129165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening and prevention of CVD
Description: Drug: Pharmacological control of risk factors in agreement with primary physicians.~Behavioral: Smoking cessation / Control of depression and anxiety / Nutritional counseling / Motivation for physical activity.~Social: Social worker care.
Study NCT04391647 — intervention group
Intervention type: OTHER
Intervention: First-void urine collection
Description: * One time collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) during visit at the Centre for the Evaluation of Vaccination.~* IF HPV positive and the woman gave consent to be contacted again: Collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) each day during 14 days (n = 14)
Study NCT04391647 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: - One time blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccination.
Study NCT04997213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Exercises
Description: Classic balance exercises were performed (two-leg stance, semi-tandem stance, tandem stance, standing on one leg, tandem walking, turning completely around, heel-to-toe stance, and standing with the eyes closed). Patients with balance disorder first could be commenced balance training in a seated position before progressing to standing exercises, to the extent that these could be tolerable.
Study NCT04661852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV, over 30 minutes (schedule based upon dose level)
Study NCT04661852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myeloid growth factor
Description: subcutaneous filgrastim (daily until ANC ≥ 1,500/mm3 after nadir) or pegfilgrastim (once) must be given, with choice of agent per institutional standard or treating physician preference, starting on day 5, 6, 7 or 8 (depending upon chemotherapy timing)
Study NCT01708616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO5285119
Description: multiple doses
Study NCT01708616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5285119
Description: multiple doses
Study NCT01708616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RO5285119 placebo
Description: multiple doses
Study NCT01708616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risperidone
Description: single dose
Study NCT01708616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: single dose
Study NCT01708616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risperidone placebo
Description: single dose
Study NCT01708616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone placebo
Description: single dose
Study NCT03299036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taiwan ACE Beads with doxorubicin
Description: Similar with commercializing drug-eluting beads, radiologist inject Taiwan ACE Beads with doxorubicin instead of Gelfoam or polyvinyl alcohol.
Study NCT03432858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin - 1-gram dosing
Study NCT03432858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: 2-gram dosing for patients \<120 kg 3-gram dosing for patients 120 kg or greater
Study NCT03432858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Placebo
Study NCT02351310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: Course of ACS given intramuscularly (2 doses of 12 mg, 24 hours apart)
Study NCT02134743 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant surgery
Description: Dental implant surgery with two different kinds of implant surface (SLA and modified SLA)
Study NCT02134743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant surgery
Description: Dental implant surgery with two different kinds of implant surface (SLA and modified SLA)
Study NCT01984203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Load Exercises
Description: All rotator cuff and scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition).
Study NCT01984203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Heavy Strength Exercises
Description: All scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The rotator cuff exercises are performed with 4 sets of gradually progressive loading and decreasing the repetitions performed in each set.~Week 1: 15reps (70% 1RM) Week 2-3: 12 reps (75% 1RM) Week 4-5: 10 reps (80% 1RM) Week 6-8: 8 reps (85% 1RM) Week 9-12: 6 reps (90% 1RM)~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition).
Study NCT03838861 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NEMO: NEw MOdel of follow-up
Description: The nurse led model is built upon phone contacts with content and intervals individually planned by the nurse and the patient. The individual contacts will be supported by graphic visualisation of ePROMs in REDCap filled out by the patient before each contact including DGCG's disease specific symptom list and the generic European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (24) supplemented with the relevant disease-specific add-on module (25, 26). The sum scores are visualised with colours to indicate severe problems (red), no problems (green) and mild or moderate problems (yellow and orange), respectively. Hence, alarm symptoms and problem areas are clearly presented to the project nurse and changes can be visualised over time enhancing the interpretation. The patient will be given access to own scoring results to obtain an understanding of the meaning of changes in health status.
Study NCT03838861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEMO: NEw MOdel of follow-up
Description: The nurse led model is built upon phone contacts with content and intervals individually planned by the nurse and the patient. The individual contacts will be supported by graphic visualisation of ePROMs in REDCap filled out by the patient before each contact including DGCG's disease specific symptom list and the generic European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (24) supplemented with the relevant disease-specific add-on module (25, 26). The sum scores are visualised with colours to indicate severe problems (red), no problems (green) and mild or moderate problems (yellow and orange), respectively. Hence, alarm symptoms and problem areas are clearly presented to the project nurse and changes can be visualised over time enhancing the interpretation. The patient will be given access to own scoring results to obtain an understanding of the meaning of changes in health status.
Study NCT02430779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Renal Pelvic and Ureteral Neoplasms guide with ultrasound or/and CT.
Study NCT02430779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study NCT01321463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: 6 mg oral tablet once daily for 12 weeks